PMGC Subsidiary NorthStrive Plans Follow-On EL-32 Study With Lower Semaglutide Dose

PUBT · 1d ago
PMGC Subsidiary NorthStrive Plans Follow-On EL-32 Study With Lower Semaglutide Dose
  • NorthStrive Biosciences, PMGC Holdings' wholly owned subsidiary, completed an eight-week EL-32 study showing no consistent added metabolic benefit over semaglutide alone.
  • High-dose EL-32 with semaglutide produced statistically greater absolute lean mass in obese mice; relative lean mass showed no significant difference.
  • The subsidiary plans another preclinical combination study using lower-dose semaglutide, with lean mass and body composition as primary endpoints.
  • An update on the follow-on study's design and timing is expected in the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050731PRIMZONEFULLFEED9870912) on November 05, 2026, and is solely responsible for the information contained therein.